Wednesday, May 14, 2014

PEG-PLGA reduces cardiotoxicity of doxorubicin during chemotherapy

PolySciTech (www.polyscitech.com) provides a wide array of PEG-PLGA copolymers. Recently these types of polymers have been found to reduce the cardiotoxicity of encapsulated doxorubicin in a rat model.  Read more: Mao, Jin Ning, Ai Jun Li, Liang Ping Zhao, Lan Gao, Wei Ting Xu, Xiao Su Hong, Wen Ping Jiang, and Jian Chang Chen. "PEG-PLGA Nanoparticles Entrapping Doxorubicin Reduced Doxorubicin-Induced Cardiotoxicity in Rats." Advanced Materials Research 912 (2014): 263-268. http://www.scientific.net/AMR.912-914.263

“Abstract: Aim:Doxorubicin-induced cardiotoxicity limited its clinical utilization in oncology. In this study, Dox was entrapped into PEG-PLGA Nanoparticles, cardiotoxicity of Dox or PEG-PLGA-Dox was investigated in rats. Materials and methods :PEG-PLGA-Dox was prepared via modified single emulsion method. Its characterization including size, Drug loading capacity (DLC), entrapment efficiency (EE) were estimated. The cardiotoxicity of PEG-PLGA-Dox was assessed on SD rats via echocardiography and biochemical indicators compare to free Dox and physical sodium. Results:The average diameter of PEG-PLGA-Dox is around 200 nm, with DLC about 10%.After administered PEG-PLGA-Dox, the ratio of heart weight to body weight decreased not as significant as Dox group, level of serum parameters and echocardiography parameter also decreased little compared to the Dox group. Conclusions: After entrapped into PEG-PLGA nanoparticle, Dox-induced cardiotoxicity was reduced significantly.”
Post a Comment